MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
34.91
+0.72
+2.11%
Closed 19:30 11/09 EST
OPEN
34.76
PREV CLOSE
34.19
HIGH
35.59
LOW
33.70
VOLUME
510.32K
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
21.95
MARKET CAP
1.91B
P/E (TTM)
-13.9056
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MAZE last week (1102-1106)?
Weekly Report · 1d ago
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
NASDAQ · 5d ago
Weekly Report: what happened at MAZE last week (1026-1030)?
Weekly Report · 11/02 09:21
Leerink Partners Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks · 10/29 12:19
Maze Therapeutics: Buy Rating Backed by MZE829 Upside in APOL1-Mediated Kidney Disease Ahead of HORIZON Phase 2 Readout
TipRanks · 10/27 00:25
Analyst Reiterates Buy on Maze Therapeutics as Phase 2 HORIZON Data for MZE829 Support APOL1 Strategy; Price Target Maintained at $110
TipRanks · 10/26 10:55
Weekly Report: what happened at MAZE last week (1019-1023)?
Weekly Report · 10/26 09:21
Maze Therapeutics: Buy Rating Reaffirmed on APOL1 Program Momentum and AMKD Market Potential; $50 Price Target Maintained
TipRanks · 10/26 00:25
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.